(Q30650589)

English

Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Psychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011 (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1 reference

based on heuristic

inferred from title

Thomas McGlashan

12

object named as

Thomas H McGlashan

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Larry J. Seidman

9

object named as

Larry J Seidman

1 reference

Europe PubMed Central

20 August 2017

PMC publication ID

Kristin S Cadenhead

4

object named as

Kristin S Cadenhead

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

2

object named as

Jean Addington

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

5

object named as

Tyrone D Cannon

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Barbara A. Cornblatt

6

object named as

Barbara A Cornblatt

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Carrie E Bearden

3

object named as

Carrie E Bearden

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

Scott W Woods

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Daniel H Mathalon

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Diana O Perkins

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Ming T Tsuang

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Elaine F Walker

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

0 references

publication date

17 June 2013

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Schizophrenia Research

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

148

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1-3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

99-104

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Early interventions to prevent psychosis: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

The psychosis high-risk state: a comprehensive state-of-the-art review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Cognitive functioning in prodromal psychosis: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Prediction and prevention of schizophrenia: what has been achieved and where to go next?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Age-grouped differences in adverse drug events from psychotropic medication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Should attenuated psychosis syndrome be a DSM-5 diagnosis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Pediatric antidepressant use after the black-box warning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

The assessment of "prodromal schizophrenia": unresolved issues and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Chlorpromazine equivalent doses for the newer atypical antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

The prodromal phase of first-episode psychosis: past and current conceptualizations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

Monitoring and care of young people at incipient risk of psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

20 June 2018

National trends in the office-based treatment of children, adolescents, and adults with antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Probably at-risk, but certainly ill--advocating the introduction of a psychosis spectrum disorder in DSM-V.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

The "prodromal" patient: both symptomatic and at-risk.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Factorial structure of the Scale of Prodromal Symptoms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Effects of development on olanzapine-associated adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Treatment histories of patients with a syndrome putatively prodromal to schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3867209

25 November 2018

Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23787224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23787224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Predictive validity of the Scale of Prodromal Symptoms (SOPS)]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23787224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.SCHRES.2013.05.019

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30650589&oldid=1930892643"